GLSI News and Press, Greenwich LifeSciences Inc. From 09/19/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Alextype/Shutterstock.com Traders continue to show interest in short squeeze stocks this week as they seek out likely targets to push higher. This has us checking out Fintel’s Short Squeeze Leaderb...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: g0d4ather / Shutterstock.com We’re starting off another week with a deep dive into the short squeeze stocks to watch! Short squeeze stocks have been popular with traders in recent months as they searc...

Summary Greenwich LifeSciences, Inc. is a one-man, one-asset shop. The asset, GP2, has produced excellent breast cancer data. Greenwich LifeSciences' CEO, Snehal Patel, runs this company almost all by himself. Greenwich LifeSciences, Inc. ( GLSI ) is a developer ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Investors looking for the most likely short squeeze stocks to watch this week are in the right place! We’re going over a list of the top five short squeeze stocks that investors will want...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the foll...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While most people don’t like to see red ink in their investment portfolios, at the same time, that negative print comes from volatility — and volatility in either direction presents opportunities for short-ter...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the foll...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the foll...

Humanigen HGEN -68% as trial for COVID-19 therapy fails . Atara Biotherapeutics ATRA -46% on interim analysis of phase 2 study for multiple sclerosis candidate. TherapeuticsMD TXMD -41% as merger agreement ends . Helius Medical Technologies ( HSDT...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: arfa adam / Shutterstock.com Versus Systems (NASDAQ: VS ) stock is rising higher on Tuesday after getting a delisting warning from the Nasdaq Exchange about a month ago. That warning gives Versus S...